UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 241

Sortiert nach

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Cancer research (Chicago, Ill.), 2017-06, Vol.77 (11), p.2990-3000

2017

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Cancer science, 2021-08, Vol.112 (8), p.3255-3265

2021

Link zum Volltext

Verfügbarkeit prüfen

Managing Lung Cancer with Comorbid Interstitial Pneumonia

Internal Medicine, 2020/01/15, Vol.59(2), pp.163-167

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-02, Vol.13 (2), p.273-279

2018

Link zum Volltext

Verfügbarkeit prüfen

Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Cancer research (Chicago, Ill.), 2016-03, Vol.76 (6), p.1506-1516

2016

Link zum Volltext

Verfügbarkeit prüfen

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer

Japanese journal of clinical oncology, 2019-08, Vol.49 (8), p.762-765

2019

Link zum Volltext

Verfügbarkeit prüfen

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease

Internal Medicine, 2021/09/01, Vol.60(17), pp.2831-2837

2021

Link zum Volltext

Verfügbarkeit prüfen

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)

Internal Medicine, 2017/08/15, Vol.56(16), pp.2195-2197

2017

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients

Japanese journal of clinical oncology, 2020-12, Vol.50 (12), p.1447-1453

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.140-146

2021

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

Cancer Immunology, Immunotherapy, 2021, Vol.70 (1), p.101-106

2021

Link zum Volltext

Verfügbarkeit prüfen

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

International journal of clinical oncology, 2019-01, Vol.24 (1), p.41-45

2019

Link zum Volltext

Verfügbarkeit prüfen

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Cancer science, 2020-10, Vol.111 (10), p.3739-3746

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection

PloS one, 2023-10, Vol.18 (10), p.e0287501-e0287501

2023

Link zum Volltext

Verfügbarkeit prüfen

SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non-small Cell Lung Cancer

Molecular cancer therapeutics, 2021-09, Vol.20 (9), p.1653-1662

2021

Link zum Volltext

Verfügbarkeit prüfen

Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis

Acta oncologica, 2020-03, Vol.59 (3), p.249-256

2020

Link zum Volltext

Verfügbarkeit prüfen

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-06, Vol.132, p.54-58

2019

Link zum Volltext

Verfügbarkeit prüfen

Subpopulation of small‐cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

Cancer science, 2013-01, Vol.104 (1), p.78-84

2013

Link zum Volltext

Verfügbarkeit prüfen

Anti-SOX1 Antibody-positive Small-cell Lung Cancer That Triggered Opsoclonus

Internal Medicine, 2023/03/15, Vol.62(6), pp.881-884

2023

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

International journal of clinical oncology, 2022-01, Vol.27 (1), p.112-120

2022

Link zum Volltext

Verfügbarkeit prüfen

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Scientific reports, 2018-01, Vol.8 (1), p.1955-11, Article 1955

2018

Link zum Volltext

Verfügbarkeit prüfen

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Cancer discovery, 2016-06, Vol.6 (6), p.601-611

2016

Link zum Volltext

Verfügbarkeit prüfen

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer

Cancer discovery, 2015-07, Vol.5 (7), p.694-696

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(235)

Publikationsform

Artikel
(234)
Berichte
(7)

Sprache

Englisch
(215)
Japanisch
(67)

Erscheinungsjahr

n.n

Thema

Science & Technology
(122)
Life Sciences & Biomedicine
(118)
Humans
(96)
Oncology
(95)
Lung Neoplasms - Drug Therapy
(59)
Female
(57)
Male
(48)
Lung Cancer
(46)
Cancer Research
(39)
Middle Aged
(38)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Lung Neoplasms - Genetics
(36)
Aged
(33)
Lung Neoplasms - Pathology
(30)
Mutation
(30)
Adult
(29)
Cell Line, Tumor
(28)
Animals
(24)
Respiratory System
(24)
Carcinoma, Non-Small-Cell Lung - Genetics
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Managing Lung Cancer with Comorbid Interstitial Pneumonia

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)

Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients

A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection

SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non-small Cell Lung Cancer

Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

Subpopulation of small‐cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy

Anti-SOX1 Antibody-positive Small-cell Lung Cancer That Triggered Opsoclonus

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer

Suchergebnisse filtern